The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy.

appropriateness drug utilization study observational study polypharmacy potentially inappropriate medication

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
20 Nov 2020
Historique:
received: 09 10 2020
revised: 14 11 2020
accepted: 17 11 2020
entrez: 25 11 2020
pubmed: 26 11 2020
medline: 26 11 2020
Statut: epublish

Résumé

We aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using data from the French National Insurance databases. The study period was from 1 January 2016 to 31 December 2016. Chronic drug use was defined as uninterrupted daily use lasting ≥6 months. Chronic polypharmacy was defined as the chronic use of ≥5 medications, and chronic hyperpolypharmacy as the chronic use of ≥10 medications. For individuals aged ≥65 (older adults), PIMs were defined according to the Beers and Laroche lists, and for individuals aged 45-64 years (middle-aged) PIMs were defined according to the PROMPT (Prescribing Optimally in Middle-aged People's Treatments) list. Among individuals with chronic polypharmacy, 4009 (46.2%) middle-aged and 18,036 (64.8%) older adults had at least one chronic PIM. Among individuals with chronic hyperpolypharmacy, these figures were, respectively, 570 (75.0%) and 2544 (88.7%). The most frequent chronic PIM were proton pump inhibitors (43.4% of older adults with chronic polypharmacy), short-acting benzodiazepines (older adults: 13.7%; middle-aged: 16.1%), hypnotics (6.1%; 7.4%), and long-acting sulfonylureas (3.9%; 12.3%). The burden of chronic PIM appeared to be very high in our study, concerning almost half of middle-aged adults and two-thirds of older adults with chronic polypharmacy. Deprescribing interventions in polypharmacy should primarily target proton pump inhibitors and hypnotics.

Identifiants

pubmed: 33233595
pii: jcm9113728
doi: 10.3390/jcm9113728
pmc: PMC7699788
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agence Nationale de Sécurité du Médicament et des Produits de Santé
ID : 2014s029

Références

PLoS One. 2014 Aug 19;9(8):e105425
pubmed: 25136981
J Am Geriatr Soc. 2015 Mar;63(3):486-500
pubmed: 25752646
Arch Intern Med. 2009 Jul 27;169(14):1326-32
pubmed: 19636035
Eur J Clin Pharmacol. 2007 Aug;63(8):725-31
pubmed: 17554532
BMC Geriatr. 2019 May 29;19(1):154
pubmed: 31142286
Laryngoscope Investig Otolaryngol. 2018 Oct 19;3(6):457-462
pubmed: 30599030
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Eur J Clin Pharmacol. 2018 Jun;74(6):679-700
pubmed: 29589066
J Neurogastroenterol Motil. 2018 Apr 30;24(2):182-196
pubmed: 29605975
BMJ. 2011 Jun 21;342:d3514
pubmed: 21693525
Am J Epidemiol. 2008 Aug 1;168(3):329-35
pubmed: 18515793
Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):3-10
pubmed: 30539229
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
BMJ. 2018 Jul 18;362:k2693
pubmed: 30021781
Ann Pharmacother. 2010 Jun;44(6):957-63
pubmed: 20460558
PLoS One. 2012;7(8):e43617
pubmed: 22928004
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
Eur J Clin Pharmacol. 2016 Jul;72(7):869-76
pubmed: 27023467
J Am Med Dir Assoc. 2017 Mar 1;18(3):211-220
pubmed: 28131719
JAMA. 2015 Nov 3;314(17):1818-31
pubmed: 26529160
Eur J Clin Pharmacol. 2012 Jul;68(7):1085-94
pubmed: 22349159
Therapie. 2020 Sep - Oct;75(5):407-416
pubmed: 31732240
Pharmacoepidemiol Drug Saf. 2006 Aug;15(8):565-74; discussion 575-7
pubmed: 16514590
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Br J Clin Pharmacol. 2010 May;69(5):543-52
pubmed: 20573091
J Am Geriatr Soc. 2015 Dec;63(12):e1-e7
pubmed: 26446776
Eur J Clin Pharmacol. 2016 May;72(5):583-91
pubmed: 26820292
BMC Geriatr. 2020 Feb 19;20(1):73
pubmed: 32075586
Ann Pharmacother. 2014 Jan;48(1):6-16
pubmed: 24396090
J Eval Clin Pract. 2016 Apr;22(2):189-93
pubmed: 26399173
Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):162-169
pubmed: 27807907
J Comorb. 2019 Aug 22;9:2235042X19870934
pubmed: 31489279
BMJ. 2018 Nov 14;363:k3532
pubmed: 30429167
Clin Epidemiol. 2018 Mar 12;10:289-298
pubmed: 29559811
Eur J Clin Pharmacol. 2015 Jul;71(7):861-75
pubmed: 25967540
Eur J Clin Pharmacol. 2015 Dec;71(12):1525-33
pubmed: 26407684
J Am Geriatr Soc. 2014 Dec;62(12):2261-72
pubmed: 25516023
Drugs Aging. 2006;23(11):915-24
pubmed: 17109569
Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1242-1247
pubmed: 28799295
BMC Health Serv Res. 2014 Oct 30;14:484
pubmed: 25410615

Auteurs

Jordan Guillot (J)

INSERM U1219, Bordeaux Population Health, Team Pharmacoepidemiology, University of Bordeaux, F-33000 Bordeaux, France.
Service de Pharmacologie Médicale, Pôle de Santé Publique, CHU de Bordeaux, 33000 Bordeaux, France.

Sandy Maumus-Robert (S)

INSERM U1219, Bordeaux Population Health, Team Pharmacoepidemiology, University of Bordeaux, F-33000 Bordeaux, France.

Alexandre Marceron (A)

Service de Pharmacologie Médicale, Pôle de Santé Publique, CHU de Bordeaux, 33000 Bordeaux, France.

Pernelle Noize (P)

INSERM U1219, Bordeaux Population Health, Team Pharmacoepidemiology, University of Bordeaux, F-33000 Bordeaux, France.
Service de Pharmacologie Médicale, Pôle de Santé Publique, CHU de Bordeaux, 33000 Bordeaux, France.

Antoine Pariente (A)

INSERM U1219, Bordeaux Population Health, Team Pharmacoepidemiology, University of Bordeaux, F-33000 Bordeaux, France.
Service de Pharmacologie Médicale, Pôle de Santé Publique, CHU de Bordeaux, 33000 Bordeaux, France.

Julien Bezin (J)

INSERM U1219, Bordeaux Population Health, Team Pharmacoepidemiology, University of Bordeaux, F-33000 Bordeaux, France.
Service de Pharmacologie Médicale, Pôle de Santé Publique, CHU de Bordeaux, 33000 Bordeaux, France.

Classifications MeSH